EBSCO Logo
Connecting you to content on EBSCOhost
Results
Title

Identification of Predictive Biomarkers for Lymph Node Involvement in Obese Women With Endometrial Cancer.

Authors

López-Ozuna, Vanessa M.; Kogan, Liron; Hachim, Mahmood Y.; Matanes, Emad; Hachim, Ibrahim Y.; Mitric, Cristina; Kiow, Lauren Liu Chen; Lau, Susie; Salvador, Shannon; Yasmeen, Amber; Gotlieb, Walter H.

Abstract

Obesity, an established risk factor for endometrial cancer (EC), is also associated to increased risks of intraoperative and postoperative complications. A reliable tool to identify patients at low risk for lymph node (LN) metastasis may allow minimizing the surgical staging and omit lymphadenectomy in obese patients. To identify molecular biomarkers that could predict LN involvement in obese patients with EC we performed gene expression analysis in 549 EC patients using publicly available transcriptomic datasets. Patients were filtrated according to cancer subtype, weight (>30 kg/m2) and LN status. While in the LN group, NEB, ANK1, AMIGO2, LZTS1, FKBP5, CHGA, USP32P1, CLIC6, CEMIP, HMCN1 and TNFRSF10C genes were highly expressed; in the LN- group CXCL14, FCN1, EPHX3, DDX11L2, TMEM254, RNF207, LTK, RPL36A, HGAL, B4GALNT4, KLRG1 genes were up-regulated. As a second step, we investigated these genes in our patient cohort of 35 patients (15 LN and 20 LN-) and found the same correlation with the in-silico analysis. In addition, immunohistochemical expression was confirmed in the tumor tissue. Altogether, our findings propose a novel panel of genes able to predict LN involvement in obese patients with endometrial cancer.

Subjects

ENDOMETRIAL cancer; LYMPHADENECTOMY; LYMPH nodes; OVERWEIGHT women; BIOMARKERS; LYMPHATIC metastasis; GENE expression; SURGICAL complications

Publication

Frontiers in Oncology, 2021, Vol 11, p1

ISSN

2234-943X

Publication type

Academic Journal

DOI

10.3389/fonc.2021.695404

EBSCO Connect | Privacy policy | Terms of use | Copyright | Manage my cookies
Journals | Subjects | Sitemap
© 2025 EBSCO Industries, Inc. All rights reserved